Acute Lymphoblastic Leukemia: a Comprehensive Review and 2017 Update

Overview

Journal Blood Cancer J

Date 2017 Jul 1

PMID 28665419

Citations 471

Authors

T Terwilliger

M Abdul-Hay

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. In adults, 75% of cases develop from precursors of the B-cell lineage, with the remainder of cases consisting of malignant T-cell precursors. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management. Despite advances in management, the backbone of therapy remains multi-agent chemotherapy with vincristine, corticosteroids and an anthracycline with allogeneic stem cell transplantation for eligible candidates. Elderly patients are often unable to tolerate such regimens and carry a particularly poor prognosis. Here, we review the major recent advances in the treatment of ALL.

Citing Articles

The rewired immune microenvironment in leukemia.

Ciantra Z, Paraskevopoulou V, Aifantis I Nat Immunol. 2025; 26(3):351-365.

PMID: 40021898 DOI: 10.1038/s41590-025-02096-9.

Artificial Intelligence Powered Automated and Early Diagnosis of Acute Lymphoblastic Leukemia Cancer in Histopathological Images: A Robust SqueezeNet-Enhanced Machine Learning Framework.

Mehan V Int J Telemed Appl. 2025; 2025:2257215.

PMID: 40017574 PMC: 11867728. DOI: 10.1155/ijta/2257215.

Development and Transportation Pathway Evaluation of Liposomes with Bile Acids for Enhancing the Blood-Brain Barrier Penetration of Methotrexate.

Charernsriwilaiwat N, Thaitrong R, Plianwong S, Opanasopit P, Songprakhon P, Subongkot T Pharmaceutics. 2025; 17(2).

PMID: 40006636 PMC: 11859986. DOI: 10.3390/pharmaceutics17020269.

Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: a prospective randomized controlled trial.

Elnaggar R, Mahmoud W, Abdrabo M, Elfakharany M Support Care Cancer. 2025; 33(3):214.

PMID: 39985582 DOI: 10.1007/s00520-025-09250-x.

Nutritional status at diagnosis and its relationship with survival and relapse in Mexican children with acute lymphoblastic leukemia: a retrospective study.

Guzman-Leon A, Gallegos-Castorena S, Romo-Rubio H, Casillas-Toral E, Lopez-Teros V, Stein K BMC Cancer. 2025; 25(1):325.

PMID: 39984931 PMC: 11846316. DOI: 10.1186/s12885-025-13729-5.

References

Shah A, John B, Sondhi V . Acute lymphoblastic leukemia with treatment--naive Fanconi anemia. Indian Pediatr. 2013; 50(5):508-10. View

Ravandi F, OBrien S, Cortes J, Thomas D, Garris R, Faderl S . Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015; 121(23):4158-64. PMC: 4666803. DOI: 10.1002/cncr.29646. View

Ning B, Tang Y, Chen Y, Shen H, Qian B . Comparison between CD19 and CD20 expression patterns on acute leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006; 13(6):943-7. View

Jacquy C, Delepaut B, Van Daele S, Vaerman J, Zenebergh A, Brichard B . A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol. 1997; 98(1):140-6. DOI: 10.1046/j.1365-2141.1997.1792996.x. View

Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris M . Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118(25):6521-8. DOI: 10.1182/blood-2011-05-351403. View

Riet T, Holzinger A, Dorrie J, Schaft N, Schuler G, Abken H . Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol. 2013; 969:187-201. DOI: 10.1007/978-1-62703-260-5_12. View

Sharkey R, Govindan S, Cardillo T, Goldenberg D . Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2011; 11(1):224-34. DOI: 10.1158/1535-7163.MCT-11-0632. View

Younes A, Kim S, Romaguera J, Copeland A, Farial S, Kwak L . Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012; 30(22):2776-82. PMC: 5950497. DOI: 10.1200/JCO.2011.39.4403. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

10.

Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

11.

Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R . Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112(4):1005-12. DOI: 10.1182/blood-2008-02-140665. View

12.

Jabbour E, Faderl S, Kantarjian H . Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005; 80(11):1517-27. DOI: 10.4065/80.11.1517. View

13.

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M . Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-36. PMC: 3720844. DOI: 10.1002/cncr.28136. View

14.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

15.

Campana D . Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2008; 46(1):100-6. PMC: 2632881. DOI: 10.1053/j.seminhematol.2008.09.001. View

16.

Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S . Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10(10):3371-6. DOI: 10.1158/1078-0432.CCR-03-0508. View

17.

OBrien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W . High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2012; 31(6):676-83. PMC: 4979201. DOI: 10.1200/JCO.2012.46.2309. View

18.

Hinman L, Hamann P, Wallace R, Menendez A, DURR F, Upeslacis J . Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 1993; 53(14):3336-42. View

19.

Yanez L, Bermudez A, Richard C, Bureo E, Iriondo A . Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia. 2009; 23(7):1342-3. DOI: 10.1038/leu.2009.58. View

20.

Dombret H, Gabert J, Boiron J, Rigal-Huguet F, Blaise D, Thomas X . Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood. 2002; 100(7):2357-66. DOI: 10.1182/blood-2002-03-0704. View